RxDoctor Payments Data

Diane Nagasaka, MD

Family Medicine · Wailuku, HINPI 1144256603

Payments from drug & device makers

$1,015in general payments, 2019–2025

Across 33 payments — averaging $30.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$302
  • Terumo Medical Corporation$164
  • Amarin Pharma, Inc.$153
  • Radius Health, Inc.$133
  • Boston Scientific$125
  • Lilly USA, LLC$54
  • plus $84 from 3 others

What the payments were for

  • Food & beverage$96595%
  • Education$505%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,015 in reported general payments places this provider in the 70th percentile of 376 family medicine providers in Hawaii.

See all family medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$52,384
Medicare patients
197
Services billed
828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab104$176,583
JanuviaSitagliptin Phosphate84$104,373
OzempicSemaglutide46$59,630
TrulicityDulaglutide36$48,402
EliquisApixaban24$23,810
Rosuvastatin Calcium195$10,587
Atorvastatin Calcium345$10,301
Wixela InhubFluticasone Propion/Salmeterol17$6,116
Felodipine ErFelodipine138$5,518
Colestipol Hcl26$4,910
Omeprazole129$3,380
Simvastatin109$3,197
Celecoxib22$2,964
Irbesartan93$2,915
Metoprolol Succinate171$2,845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$302$176,583104 claims
Novo NordiskOzempic$48$59,63046 claims
Lilly USA, LLCTrulicity$54$48,40236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 376 family medicine providers in Hawaii.

Other family medicine in Wailuku

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →